[HTML][HTML] Subcutaneous REGEN-COV antibody combination in early asymptomatic SARS-Cov-2 infection: a randomized clinical trial
MP O'Brien, E Forleo-Neto, N Sarkar, F Isa, P Hou… - MedRxiv, 2021 - ncbi.nlm.nih.gov
MedRxiv, 2021•ncbi.nlm.nih.gov
Objective: Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab
antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-
CoV-2 infection to COVID-19. Design: Randomized, double-blind, placebo-controlled, phase
3 study that enrolled asymptomatic close contacts living with a SARS-CoV-2–infected
household member (index case). Participants who were SARS-CoV-2 RT-qPCR–positive at
baseline were included in the analysis reported here. Setting: Multicenter trial conducted at …
antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-
CoV-2 infection to COVID-19. Design: Randomized, double-blind, placebo-controlled, phase
3 study that enrolled asymptomatic close contacts living with a SARS-CoV-2–infected
household member (index case). Participants who were SARS-CoV-2 RT-qPCR–positive at
baseline were included in the analysis reported here. Setting: Multicenter trial conducted at …
Objective:
Evaluate the efficacy and safety of subcutaneous casirivimab and imdevimab antibody combination (REGEN-COV) to prevent progression from early asymptomatic SARS-CoV-2 infection to COVID-19.
Design:
Randomized, double-blind, placebo-controlled, phase 3 study that enrolled asymptomatic close contacts living with a SARS-CoV-2–infected household member (index case). Participants who were SARS-CoV-2 RT-qPCR–positive at baseline were included in the analysis reported here.
Setting:
Multicenter trial conducted at 112 sites in the United States, Romania, and Moldova.
Participants:
Asymptomatic individuals≥ 12 years of age were eligible if identified within 96 hours of collection of the index case’s positive SARS-CoV-2 test sample.
Interventions:
A total of 314 asymptomatic, SARS-CoV-2 RT-qPCR–positive individuals living with an infected household contact were randomized 1: 1 to receive a single dose of subcutaneous REGEN-COV 1200mg (n= 158) or placebo (n= 156).
ncbi.nlm.nih.gov
以上显示的是最相近的搜索结果。 查看全部搜索结果